- Short communication
- Open Access
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
EJNMMI Research volume 11, Article number: 74 (2021)
89Zirconium-immuno-positron emission tomography (89Zr-immuno-PET) is used for assessment of target status to guide antibody-based therapy. We aim to determine the relation between antibody tumor uptake and target concentration to improve future study design and interpretation.
The relation between tumor uptake and target concentration was predicted by mathematical modeling of 89Zr-labeled antibody disposition in the tumor. Literature values for trastuzumab kinetics were used to provide an example.
89Zr-trastuzumab uptake initially increases with increasing target concentration, until it levels off to a constant value. This is determined by the total administered mass dose of trastuzumab. For a commonly used imaging dose of 50 mg 89Zr-trastuzumab, uptake can discriminate between immunohistochemistry score (IHC) 0 versus 1–2–3.
The example for 89Zr-trastuzumab illustrates the potential to assess target expression. The pitfall of false-positive findings depends on the cut-off to define clinical target positivity (i.e., IHC 3) and the administered mass dose.
89Zr-immuno-PET is used in clinical studies as a non-invasive method to quantify tumor uptake of 89Zr-labeled monoclonal antibodies (mAbs). A potential application is to non-invasively assess target expression in-vivo. If reliable, this knowledge may help to decide whether individual patients may benefit from drugs aimed at this target. However, unexplained false-positivity occurs , hampering clinical applications.
An example is the use of 89Zr-trastuzumab to assess human epidermal growth factor receptor 2 (HER2) expression in-vivo. The goal is to predict which patients are likely to respond to treatment with trastuzumab or trastuzumab-based antibody–drug conjugates. Ideally, tumor uptake on PET should be high for HER2-positive tumors (IHC 3, 2/fluorescence in situ hybridization (FISH) amplified), and low for HER2-negative tumors (IHC 0, 1, 2/FISH non-amplified).
Our aim is to use mathematical modelling of antibody disposition in the tumor to demonstrate how tumor uptake of 89Zr-immuno-PET is related to the target concentration.
This general method will be illustrated using 89Zr-trastuzumab as an example to improve our understanding of false-positive findings.
Materials and methods
We developed a mathematical model to predict tumor uptake [in terms of standardized uptake value (SUV)] as a function of time. Here, we first define the biological processes involved in mAb extravasation and target interaction. Next, we describe the parameters used to model these processes. Finally, we describe implementation of the model.
Tumor tissue consists of vascular, interstitial and cellular spaces (Fig. 1a). Immediately after intravenous administration, all mAb is present in the vascular space (Fig. 1b). mAb extravasates as the concentration of unbound mAb in interstitial space is lower than the concentration of mAb in vascular space, with the concentration gradient as the driving force of extravasation. The extravasation rate constant determines the amount of mAb that can extravasate for a given concentration gradient. This rate constant combines the permeability of the vasculature and the degree of vascularization of the tissue. Thus, mAb is transported from vascular to interstitial space until the concentrations of mAb in the vascular and interstitial space are equal (Fig. 1c). When mAb binds to target, the concentration of unbound mAb in interstitial space decreases, resulting in an increased amount of extravasating mAb (Fig. 1d). The concentration of targets available for binding is determined by the initial target concentration as well as target kinetics.
The parameters used to describe tumor uptake are given in Table 1. They include tumor tissue characteristics (vascular and interstitial volume fractions and the extravasation rate constant) and target-related parameters (initial target concentration, equilibrium binding affinity and target synthesis, degradation and mAb-target internalization rates). To obtain typical values for these parameters, a literature search was performed. Per parameter, its value is given together with the literature references on which this value is based (see Table 1). The remaining parameters include those used to characterize systemic plasma PK. Our description of plasma pharmacokinetic (PK), needed in the model to drive tumor uptake, is in the form of a 2 compartment model.
We assume that:
The biological processes and all parameters apply the same to unlabeled mAb as well as 89Zr-mAb
The combined concentration of mAb and 89Zr-mAb in the interstitial space determines the fraction of antibody bound to target 
The intracellular concentration of 89Zr does not decrease after internalization and metabolization of a 89Zr-mAb-target complex, since it is a residualizing radionuclide 
The structure of the mathematical model is shown in Fig. 2. In the model equations the subcript j refers to either unlabeled mAb (j = u) or labeled 89Zr-mAb (j = l).
The amount of (89Zr-)mAb is plasma is:
The amount of (89Zr-)mAb in remainder of body is:
The amount of (89Zr-)mAb in the interstitial space of the tumor is:
The fraction unbound (89Zr-)mAb in the interstitial space of the tumor is calculated as:
The target concentration is given by:
The amount of residualized 89Zr after internalization of 89Zr-mAb is given by:
The total 89Zr concentration in the tumor is:
The measured 89Zr uptake in SUV is:
Model simulations were performed using Berkely Madonna (version 8.3.18).
To evaluate the performance of the model we selected literature data on a 89-Zr labeled antibody against a well characterized target with measured plasma PK as well as tumor uptake as a function of time. Plasma PK as well as tumor uptake data for 89Zr-trastuzumab at an administered dose of 50 mg were obtained from literature . Plasma PK data were digitized using Plot Digitizer (http://plotdigitizer.sourceforge.net/) and fitted to a bi-exponential curve using Matlab (version R2017b). The rate constants for exchange and clearance are calculated as outlined in  and given in Table 1. The sensitivity of model output to model parameters was assessed by evaluating the percentage change in model output with the change of model parameter by + 10% . Parameters with a sensitivity smaller than 2% are not considered sensitive.
Tumor uptake without HER2 expression as a function of time
Figure 3 shows the model derived tumor uptake of 89Zr-trastuzumab data for an administered dose of 50 mg (panel a; model ouput is based on the values in Table 1 with the intitial target concentration T0 = 0 nM, dashed line). For reference, also the plasma PK curve is given (panel b; not predicted in the model but used as an input function obtained from literature). Tumor uptake increases over time until plasma and interstitial concentrations are equal (Fig. 3b). From then on (typically after 24 h p.i.), tumor uptake decreases over time, proportional to the decrease in plasma concentration, since there is no driving force for extravasation (Fig. 1c). In case there is zero HER2 expression in the tumor, the model predicts a tumor SUV of ~ 2 at 120 h p.i., ~ 24% of the plasma SUV at this point in time (the sum of the vascular and mAb accessible interstitial volume fractions).
Tumor uptake with HER2 expression as a function of time
For a clinically HER2-positive tumor (IHC3), tumor uptake increases over time, as no equilibrium is reached between the concentrations of unbound 89Zr-mAb in plasma and in interstitial space (Fig. 3a; model output is based on the values in Table 1, with T0 = 2700 nM, solid line). In this case, every mAb molecule entering the interstitial space will bind to a target (due to the abundance of free targets). Therefore, the interstitial concentration of unbound 89Zr-mAb is nearly zero and the driving force remains (Fig. 1d). The extravasation rate constant is the only parameter that impacts the predicted SUV at 120 h p.i., and a SUV of 19 is predicted at the value of 0.012 h−1 for the extravasation rate constant (see Table 1). The clinical study on 89Zr-trastuzumab from which the plasma PK data are taken reports a range in SUV from 2.5 to 20.2  for HER2-positive tumors (all IHC3). This results in a range in extravasation rate constant from 0.0014 to 0.0128 h−1 (obtained by changing the value of this rate constant and keeping the other parameter values as given in Table 1).
Tumor uptake as a function of HER2 concentration
At an administered dose of 50 mg, tumor uptake increases with increasing HER2 concentration from 1 to ~ 50 nM (Fig. 4; model ouput is based on the values in Table 1, with T0 ranging from 0 to 1000 nM). With increasing target concentration, the concentration of unbound antibody in the interstitial space decreases. Thus, the amount of mAb extravasating increases and results in a higher total uptake of mAb in the tumor. For target concentrations above 50 nM a plateau in SUV is reached, as there is an overload of targets for the amount of antibody administered (the concentration unbound mAb in the interstitial space is close to zero). The factor that determines the maximum tumor uptake is not the target concentration, but the extravasation rate constant.
89Zr-immuno-PET is a promising in-vivo tool to determine the presence of target expression and to quantify tumor uptake of 89Zr-labeled mAbs. Tumor uptake is determined by multiple factors, including mAb extravasation and target interaction.
Here we demonstrate the relation between tumor uptake and target concentration. Conceptually, a target-negative tumor can be distinguished from a target-positive tumor by 89Zr-immuno-PET, assuming other tumor characteristics are similar (Fig. 3). At a mass dose of 50 mg 89Zr-trastuzumab in a trastuzumab-naïve patient, we found that tumor SUV can distinguish between IHC0 and IHC1-2–3 (Fig. 4). This result may explain false-positive findings as described in literature, since tumor SUV cannot distinguish between IHC1-2–3.
So far, no clinical data is available for validation of tumor uptake for tumors that do not express the target. For HER2-negative tumors (for which limited HER2 expression cannot be excluded) a median SUV of 3.1 (range 2.0–5.7) was reported in literature . Interestingly, HER2-negative tumors with hepatic localization showed a higher SUV than non-hepatic lesions (7.9 vs. 2.8). This may be due to a higher extravasation rate constant for tumors located in the liver.
When considering the use of a SUV threshold to assess target status it is important to realize that the rate of extravasation is the key factor that determines the maximum tumor uptake. This tumor characteristic is expected to vary between and within patients (e.g., for tumor type and localization). In addition, as plasma clearance increases, e.g., due to the presence of an antigen sink , uptake will be lower due to the lower concentration of mAb in plasma. Published plasma PK curves at 1 mg/kg and 8 mg/kg can be used to explore the effect of an increase in total mass dose on tumor uptake . At 120 h p.i., SUV is predicted to increase from 21 to 26. Although the absolute amount of mAb in the tumor is much higher in the latter case, this is not reflected in the SUV as this uptake value relates to labeled mAb only.
Further experimental validation of the mathematical model will be possible with increasing availability of total-body PET scanners, mainly through their ability to better define tumor uptake as a function of time.
The general framework designed in this study can be applied to improve future clinical 89Zr-immuno-PET studies. For a novel antibody with different target kinetics, the relation between SUV and target concentration can be predicted by inserting the corresponding target parameters in the model.
We demonstrated how tumor uptake as assessed by 89Zr-immuno-PET is related to the target concentration, using mathematical modeling of 89Zr-labeled antibody disposition in the tumor.
The example for 89Zr-trastuzumab illustrates the potential to assess target status. The pitfall of false-positive findings depends on the target concentration used to clinically define target positivity and on the administered mass dose.
Availability of data and materials
All data generated and analysed in this study are included in this published article.
Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-trastuzumab PET/CT for detection of human epidermal growth factor receptor 2-positive metastases in patients with human epidermal growth factor receptor 2-negative primary breast cancer. Clin Nucl Med. 2017;42(12):912–7.
Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci. 2010;99(3):1582–600.
Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35(5):899–908.
O’Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, Larson SM, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med. 2018;59(1):161–6.
Hull CJ. Pharmacokinetics and pharmacodynamics. Br J Anaesth. 1979;51(7):579–94.
Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, et al. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat. 2018;169(3):523–30.
Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586–92.
Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer. 1999;81(8):1419–25.
Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J. 2012;14(3):612–8.
Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039–51.
Krol A, Maresca J, Dewhirst MW, Yuan F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res. 1999;59(16):4136–41.
Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421–34.
Thurber GM, Dane WK. A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol. 2012;314:57–68.
Glassman PM, Balthasar JP. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2016;43(4):427–46.
Orcutt KD, Adams GP, Wu AM, Silva MD, Harwell C, Hoppin J, et al. Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: application to molecular imaging. Mol Imaging Biol. 2017;19(5):656–64.
Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res. 2003;284(1):78–88.
Ethics approval and consent to participate
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Huisman, M.C., Menke-van der Houven van Oordt, C.W., Zijlstra, J.M. et al. Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example. EJNMMI Res 11, 74 (2021). https://doi.org/10.1186/s13550-021-00813-7
- Molecular imaging
- Monoclonal antibody
- Target expression